News – Page 964 – Endpoints News

MorphoSys taps Bavencio lead for US operations; Two top FDA officials move to industry

7 years ago

Should J&J win an OK for a flawed depression drug after notable trial failures? FDA review offers a path forward

7 years ago

Rutgers scientists form immuno-oncology biotech to develop pipeline of TAM inhibitors

7 years ago

Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer

7 years ago

Encouraging gene therapy data give uniQure an injection of confidence as it preps PhIII showdown with Spark

7 years ago

2019's second unicorn Gossamer raises $276M in upsized IPO offering, MPM's Harpoon makes its Nasdaq debut with $75.6M ...

7 years ago

Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today

7 years ago

Researchers spotlight a basket of 'good' response rates for the next ADC in Seattle Genetics' pipeline

7 years ago

Sangamo shares take a big hit as investors react to setback for pioneering gene-editing tech

7 years ago

Tightening its wallet for a clinical comeback, Seres lets go of CSO and 30% of workforce

7 years ago

Equillium's immuno-inflammatory drug wins FDA's orphan drug status; Vanda sues FDA for mandating lengthy dog study

7 years ago

Rare pediatric PRV program not linked to uptick in new drugs starting trials, study finds

7 years ago

As magnitude and frequency of drug price hikes thaw, Express Scripts reports lowest increase in spending by ...

7 years ago

Alnylam shores up enthusiasm for givosiran with early dataset ahead of crucial PhIII readout

7 years ago

Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD

7 years ago

The biotech unicorns are back: Alector burnishes its $1.3B valuation in an IPO that generates $176M in cash

7 years ago

Arch joins Celgene, China investors bankrolling a pioneering New York biotech startup focused on a new approach to ...

7 years ago

Burnishing its rare disease drug ambitions, Sanofi picks up fast FDA OK for Cablivi — courtesy of a $4.8B buyout

7 years ago

Split up the chairman/CEO role at Allergan — activist investor; Zogenix files for FDA, EMA approval of seizure drug

7 years ago

Hal Barron’s GSK team continues to cull respiratory drugs in big shift to oncology R&D

7 years ago

Three senior Chimerix execs to hold the fort to replace departing CEO Berrey

7 years ago

Basking in praise and a $4.2B GSK pact, Merck KGaA blueprints expansion plans for Boston-area R&D campus

7 years ago

Avrobio takes a second stab at a good first impression — but durability questions still dog gene therapy

7 years ago

Capricor to resume dosing in DMD trial — but scarce resources force company to pause enrollment, cut jobs

7 years ago

First page Previous page 961 962 963964965 966 967 Next page Last page